Overview

Oral Liquid 13-cis-retinoic Acid (13-CRA)

Status:
Completed

Trial end date:
2019-09-12

Target enrollment:

Participant gender:

Summary

An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - < 21 years.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nova Laboratories Limited

Treatments:

Isotretinoin
Tretinoin